EVT201

EQS-News: Evotec-partner Jingxin receives approval for EVT201 in China

Retrieved on: 
Thursday, December 14, 2023
Frankfurt Stock Exchange, ALL, MDAX, Incidence, EVT201, EVO, GABAA, Woman, Partnership, LTD, ISIN, KOREA, Pharmaceutical industry, Insomnia, Evotec

EVOTEC’S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (“JINGXIN”) WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA

Key Points: 
  • EVOTEC’S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (“JINGXIN”) WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA
    Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Zhejiang Jingxin Pharmaceutical Co., Ltd (“Jingxin”) has received the approval from the Chinese National Medical Products Administration (“NMPA”) for the novel insomnia treatment EVT201, also known as Dimdazenil in China.
  • The Company led clinical Phase II development for EVT201, yielding positive safety and efficacy results, before licensing the programme out to Jingxin for further development and commercialisation in China.
  • Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are excited to see Jingxin announce the approval of EVT201 as a novel short-term treatment of insomnia.
  • We have full confidence in our partner Jingxin for the commercialisation of EVT201 in China and South Korea to respond to the unmet medical need of insomnia patients.”

DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates

Retrieved on: 
Thursday, August 11, 2022
Digital technology, Drug discovery, Growth, ISIN, EVT201, CGMP, DMPK, Financial Oversight and Management Board for Puerto Rico, Research, Centauri, Frankfurt Stock Exchange, MDAX, Therapy, EBITDA, Boehringer Ingelheim, COVID-19, Acquisition, Biopharmaceutical, Goal, BAY, CMC, Innovation, IndiGo, Security (finance), Semiconductor, Pharmaceutical industry, Fine chemical

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced its financial results for the first half-year of 2022.
  • Group revenues increased by 24% to 336.9m (H12021: 271.3m) driven by strong demand for its base business; like-for-like revenue growth (excluding fx-effects) 19%
    Continued strong revenue growth momentum: Total EVT Execute revenues (incl.
  • Several new integrated drug discovery collaborations signed, including INDiGO, CMC and DMPK agreements
    Just Evotec Biologics: Just Evotec Biologics is currently in its initial build up phase.